Open AccessTreatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
Author(s) -
Sharon Walmsley,
Laurent Cotte,
Stefano Rusconi,
Douglas J. Ward,
Charles B. Hicks,
Ulrich Meier,
Hernán Valdez,
Charles A. Boucher
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3282ef6db7
Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , medicine , virology , protease inhibitor (pharmacology) , pharmacology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.